MedTrace Logo

Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP

NCT05667636 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2022-12-28

No results posted yet for this study

Summary

After radical prostatectomy, 30-60% of patients will develop recurrent disease. Salvage radiotherapy, usually at 2 Gy per fraction, is the main treatment option for these patients.

The aim of the present study is to determine the 3-yr biochemical failure free survival of the stereotactic approach in 5 fractions in the context of salvage radiotherapy for biochemical failure after radical prostatectomy.

Conditions

  • Prostatic Neoplasm

Interventions

RADIATION

salvage SBRT

steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer

Sponsors & Collaborators

  • Alessia Farneti

    collaborator UNKNOWN

  • Adriana Faiella

    collaborator UNKNOWN

  • Marta Bottero

    collaborator UNKNOWN

  • Pasqualina D'Urso

    collaborator UNKNOWN

  • Valeria Landoni

    collaborator UNKNOWN

  • Antonella Soriani

    collaborator UNKNOWN

  • Luca Bertini

    collaborator UNKNOWN

  • Regina Elena Cancer Institute

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-27
Primary Completion
2023-09-27
Completion
2024-09-27

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667636 on ClinicalTrials.gov